Day: March 20, 2024

HENDERSON, Nev., March 20, 2024 (GLOBE NEWSWIRE) — Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024. On August 1, 2022, Nika Pharmaceuticals, Inc. signed a Cooperation Agreement with Nika BioTechnology, Inc., pursuant to which the companies would develop separate regions for the respective pharmaceutical products whilst splitting the cost and net profit in equal parts. The merger is the evolution of this cooperation, as it consolidates the business into one entity and will provide a much more resilient and sustainable corporate structure, on which the business development may flourish. The company believes that the merger will bring a myriad of benefits, including but not limited to:Decrease in operational costs, which will free up funds for additional...

Murano Global Investments Ordinary Shares and Warrants to trade on Nasdaq under new ticker symbol “MRNO” and “MRNOW” LONDON, March 20, 2024 (GLOBE NEWSWIRE) — Murano Global Investments Plc. (“Murano” or the “Company”), a London headquartered real estate company that owns, develops and invests in hotel, resort and commercial properties throughout Mexico, announces today that it has completed its business combination with HCM Acquisition Corp (NASDAQ: HCMA) (“HCM”), a special purpose acquisition company. The business combination was approved by HCMA stockholders in a special meeting held on March 5th 2024. The combined company will operate as Murano Global Investments and its common stock and warrants will begin trading on Thursday, March 21, 2024 on the Nasdaq Capital Market under the ticker symbols “MRNO” and “MRNOW”, respectively. “Becoming...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE / DEALING BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR   MORE   Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: AXA Investment Managers S.A.(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Ageas SA/NV(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE / DEALING BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR   MORE   Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: AXA Investment Managers S.A.(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Ageas SA/NV(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...